Next-generation sequencing of primary tumors is now standard for transcriptomic studies, but microarray-based data still constitute the majority of available information on other clinically valuable samples, including archive material. Using prostate cancer (PC) as a model, we developed a robust analytical framework to integrate data across different technical platforms and disease subtypes to connect distinct disease stages and reveal potentially relevant genes not identifiable from single studies alone. We reconstructed the molecular profile of PC to yield the first comprehensive insight into its development, by tracking changes in mRNA levels from normal prostate to high-grade prostatic intraepithelial neoplasia, and metastatic di...
Prostate cancer is a clinically and biologically heterogeneous disease. Deregulation of splice varia...
Although genome-wide association studies (GWAS) for prostate cancer (PrCa) have identified more than...
BACKGROUND: Although chemotherapy for prostate cancer (PCa) can improve patient survival, some tumou...
AbstractBackgroundUnderstanding the heterogeneous genotypes and phenotypes of prostate cancer is fun...
Study data are deposited in NCBI GEO (unique identifier number GSE70770).Background : Understanding ...
SummaryMolecular profiling of cancer at the transcript level has become routine. Large-scale analysi...
BACKGROUND: Understanding the heterogeneous genotypes and phenotypes of prostate cancer is fundament...
This is the final version. Available on open access from BMC via the DOI in this recordAvailability ...
Background: Understanding the heterogeneous genotypes and phenotypes of prostate cancer is fundament...
SummaryAnnotation of prostate cancer genomes provides a foundation for discoveries that can impact d...
Intra-tumor heterogeneity is one of the biggest challenges in cancer treatment today. Here we invest...
Background Understanding the heterogeneous genotypes and phenotypes of prostate cancer is fundamenta...
AbstractProstate tumors are among the most heterogeneous of cancers, both histologically and clinica...
Prostate cancer affects millions of people worldwide. The current risk stratification and disease ma...
Although genome-wide association studies (GWAS) for prostate cancer (PrCa) have identified more than...
Prostate cancer is a clinically and biologically heterogeneous disease. Deregulation of splice varia...
Although genome-wide association studies (GWAS) for prostate cancer (PrCa) have identified more than...
BACKGROUND: Although chemotherapy for prostate cancer (PCa) can improve patient survival, some tumou...
AbstractBackgroundUnderstanding the heterogeneous genotypes and phenotypes of prostate cancer is fun...
Study data are deposited in NCBI GEO (unique identifier number GSE70770).Background : Understanding ...
SummaryMolecular profiling of cancer at the transcript level has become routine. Large-scale analysi...
BACKGROUND: Understanding the heterogeneous genotypes and phenotypes of prostate cancer is fundament...
This is the final version. Available on open access from BMC via the DOI in this recordAvailability ...
Background: Understanding the heterogeneous genotypes and phenotypes of prostate cancer is fundament...
SummaryAnnotation of prostate cancer genomes provides a foundation for discoveries that can impact d...
Intra-tumor heterogeneity is one of the biggest challenges in cancer treatment today. Here we invest...
Background Understanding the heterogeneous genotypes and phenotypes of prostate cancer is fundamenta...
AbstractProstate tumors are among the most heterogeneous of cancers, both histologically and clinica...
Prostate cancer affects millions of people worldwide. The current risk stratification and disease ma...
Although genome-wide association studies (GWAS) for prostate cancer (PrCa) have identified more than...
Prostate cancer is a clinically and biologically heterogeneous disease. Deregulation of splice varia...
Although genome-wide association studies (GWAS) for prostate cancer (PrCa) have identified more than...
BACKGROUND: Although chemotherapy for prostate cancer (PCa) can improve patient survival, some tumou...